MAP2K7 and melanoma: In more recent years, anti-PD-1 for metastatic melanoma patients [31,32,33,34,35,36], and anti-BRAF/MEK for those with BRAF mutations [39,40,41,42], have had a profound effect on the survival of patients with advanced melanoma.